![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-218x150.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
UTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2022 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology firm targeted on creating its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers, right now introduced the Company will current knowledge demonstrating on-mechanism pharmacodynamics for LAVA-051 within the clinic in the course of the Society for Immunotherapy of Cancer’s 37th Annual Meeting, going down in Boston, Massachusetts and nearly from November 8-12, 2022.
The particulars of the poster presentation session are as follows:
Abstract #: 686
Abstract Title: Mechanism of motion of LAVA-051, a bispecific Vγ9Vδ2 T-cell engager (bsTCE), confirmed within the medical setting
Session Title: Cellular Therapies + Bispecifics
Session Date: Friday, November 11, 2022
Session Time: 9:00 a.m.–8:30 p.m. EST/3:00 p.m.–2:30 a.m. CET
Presenter: Benjamin Winograd, M.D., Ph.D., chief medical officer, LAVA Therapeutics
About LAVA Therapeutics
LAVA Therapeutics N.V. is a clinical-stage immuno-oncology firm using its proprietary Gammabody™ platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential therapy of strong and hematological malignancies. The Company makes use of bispecific antibodies engineered to selectively kill most cancers cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector capabilities upon cross-linking to tumor-associated antigens. For extra data, please go to www.lavatherapeutics.com, and observe us on LinkedIn, Twitter and YouTube.
LAVA’s Cautionary Note on Forward-Looking Statements
This press launch comprises forward-looking statements, together with with respect to the corporate’s anticipated progress and medical growth plans, together with the timing of medical trials. Words reminiscent of “anticipate,” “believe,” “could,” “will,” “may,” “expect,” “should,” “plan,” “intend,” “estimate,” “potential” and related expressions (in addition to different phrases or expressions referencing future occasions, circumstances or circumstances) are supposed to determine forward-looking statements. These forward-looking statements are primarily based on LAVA’s expectations and assumptions as of the date of this press launch and are topic to varied dangers and uncertainties that will trigger precise outcomes to differ materially from these forward-looking statements. Forward-looking statements contained on this press launch embody, however will not be restricted to, statements in regards to the preclinical knowledge, medical growth and scope of medical trials, and the potential use of our product candidates to deal with varied tumor targets. Many components, dangers and uncertainties might trigger variations between present expectations and precise outcomes together with, amongst different issues, the timing and outcomes of our analysis and growth applications and preclinical and medical trials, our capacity to get hold of regulatory approval for and commercialize our product candidates, our capacity to leverage our preliminary applications to develop further product candidates utilizing our Gammabody™ platform, and the failure of LAVA’s collaborators to help or advance collaborations or our product candidates. The COVID-19 pandemic might disrupt our business and that of the third events on which we rely, together with delaying or in any other case disrupting our medical trials and preclinical research, manufacturing and provide chain, or impairing worker productiveness. In addition, there could also be antagonistic results on our business situation and outcomes from common financial and market circumstances and general fluctuations within the United States and worldwide fairness markets, together with deteriorating market circumstances due to investor considerations relating to inflation and hostilities between Russia and Ukraine. LAVA assumes no obligation to replace any forward-looking statements contained herein to replicate any change in expectations, at the same time as new data turns into obtainable.
CONTACTS
Investor Relations
[email protected]
Argot Partners (IR/Media)
212-600-1902
[email protected]
